Jump to content

Julie Overbaugh

Edit links
From Wikipedia, the free encyclopedia
Julie Overbaugh
Born
Pennsylvania, USA
Academic background
EducationBS, chemistry, 1979, University of Connecticut
Ph.D., Biochemistry, 1983, University of Colorado Boulder
ThesisMicrobial glutathoine peroxidases and transferases (1983)
Academic work
InstitutionsFred Hutchinson Cancer Research Center
University of Washington
Harvard

Julie M. Overbaugh is an American virologist. She is a professor at the Fred Hutchinson Cancer Research Center. Overbaugh is best known for her translational approach to studying HIV transmission and pathogenesis and studies of how the antibody response evolves to recognize viruses. Her work in maternal and infant HIV transmission helped make clear the risk posed by breastfeeding and highlighted unique characteristics of an infant immune response that could inform vaccine development. Major scientific contributions to the understanding of HIV transmission and pathogenesis also include: identifying a bottleneck that selects one or a few variants during HIV transmission; demonstrating the importance of female hormones in HIV infection risk; showing the HIV reinfection is common; demonstrating a role for antibodies that mediate ADCC in clinical disease; showing that HIV infected infants develop unique neutralizing antibody responses to HIV.

Overbaugh is an elected member of the National Academy of Sciences and the American Academy of Arts and Sciences. In addition to being recognized for her scientific contributions, she is also recognized for her mentoring, her advocacy for equity and her commitment to global health.

Early life and education

[edit]

Overbaugh was born and raised in Pennsylvania[1] and graduated from Delone Catholic High School in 1975.[2] During high school, she captained their basketball and field hockey teams and received an award for Excellence in Athletics.[3]

Following high school, Overbaugh was recruited to play college basketball for the University of Connecticut's Huskies from 1976 to 1978. During her tenure, she averaged 3.5 points in 46 games, and also played varsity tennis and served as team captain during her final year.[4] She graduated with a Bachelor of Science degree in chemistry in 1979 and earned her PhD in chemistry from the University of Colorado Boulder. During her PhD, Overbaugh spent four months in Oklahoma aiding the effort to ratify the Equal Rights Amendment.[5] She returned to school to complete her PhD and continued her training as a postdoctoral fellow in interdisciplinary programs in health and cancer biology at the Harvard T.H. Chan School of Public Health from 1983 to 1987. During her fellowship, she became interested in HIV research because it was a "clear intersection of science and public health and medicine."[6]

Career

[edit]

Following her fellowship, Overbaugh joined the University of Washington (UW) to expand their HIV research program to include a basic science focus.[1] In 1992, she became a member of the Nairobi HIV/STD Research Project, which included collaborating on a study of HIV mother-infant infection.[2] For this, she joined Joan Kreiss and Ruth W. Nduati in Kenya to understand the risk of HIV transmission through breastfeeding. The research team found that breastfeeding doubled the risk of HIV transmission from mother to child.[7][8] Her subsequent studies showed that the levels of virus in breastmilk predicted infection risk.[9][10]

Overbaugh left the UW in 1999 to join the Fred Hutchinson Cancer Research Center where she continued and expanded her studies of HIV transmission and pathogenesis, including working closely with the Kenya research collaborative team.. That year Overbaugh received an Elizabeth Glaser Scientist award to expand her studies of mother-infant transmission of HIV to better understand how features of the virus and immune response impact infant infection risk.[2] They went on to define immune factors that impact transmission in the setting of infant exposure, particularly a role for non-neutralizing antibodies that mediated cell killing in infant infection and disease [11][12] Her research team also discovered novel aspects of the infected infant's immune response to HIV and isolated and characterized the first HIV neutralizing antibodies from infants.[13][14][15][16][6] They also discovered a variant of HIV in an infant, BG505, that has been extensively leveraged for studies of HIV structure and for vaccine development.[17]

Overbaugh's research has also focused on understanding how viral evolution impacts disease and she showed that the viruses that evolve over the course of infection are more pathogenic, in part because they have escaped neutralizing antibody control.[18][19][20] Her work also highlighted that retroviruses can evolve to change their entry receptors and by so doing, can infect new cells and cause changes in disease outcomes.[21][22][23][24][25][26][27] She also discovered that HIV adapted in cell culture can use more diverse receptor othologues, and that this adaption makes strains used in model system distinct [28][29][30] In her very early work, Overbaugh also studied adaptive evolution.[31]

Her work with the Kenya research collaborative team also included expanding studies with Kreiss to better define the basis of transmission in high-risk women, such as sex workers,[5] work that continues to this day in Mombasa, Kenya. There, a focus of her research has been on the early dynamics of infection. Her group showed that despite chronically infected people having many distinct viral variants of HIV, there was the transmission of just one or a few of these variants, indicating a bottleneck in viruses that are transmitted.[32][33][34] They went on to show that the transmission bottleneck is influenced by his factors such as hormonal contraceptives and sexually transmitted diseases.[35] Her group further showed that transmission can also occur in the face of an existing infection, leading to re-infection,[36][37][38] and her team has studied the setting of re-infection to understand immune correlates of protection to inform vaccine efforts.[39][40][41]

Overbaugh was also involved with collaborated studies to define antibody escape pathways for HIV antibodies and the molecular determinants that govern HIV entry into host cells.[42][43][44] Her lab went on to develop a method to profile escape called Phage-DMS that has been used for studies of HIV and SARS-CoV-2.[45][46]

Due to her interest in infectious disease of global health importance, Overbaugh also emphasized the development of methods for detecting infections in her work. Because HIV strains in Africa differed from those in the US, she developed methods to detect infection with those strains and helped validate assays to define the levels of infection.[47][48][49] More recently, she extended this approach to develop methods for detecting antibodies to SARS-CoV-2.[50]

Major awards

[edit]

Overbaugh received the Elizabeth Glaser Scientist Award for her work in pediatric HIV research in 1999.[2] In 2011, Overbaugh was named FierceBiotech's 2011 Women in Biotech[51] and was elected to the American Society for Microbiology.[52] Later that year, Overbaugh received the Marion Spencer Fay Leadership Award Drexel University’s Institute for Women's Health and Leadership.[53] In 2016, she also received the lifetime achievement Nature Award for Mentoring in Science and was the first US-Based scientists to be recognized with this award.[5] Two years later, she was recognized for her long service to the global fight against HIV with the Field's Memorial Lecture at the opening session of the Conference on Retroviruses and Opportunistic Infections.[54] As a result of her studies of HIV transmission and pathogenesis in affected cohorts, including African women and children, she was elected a Fellow of the American Academy of Arts and Sciences.[55][56] She was also elected a Member of the National Academy of Sciences for her studies of HIV transmission and pathogenesis in affected cohorts, including African women and children; she is the first Seattle-based virologist to be elected to the prestigious NAS.[57]

Mentoring

[edit]

Overbaugh has been recognized in various ways for her mentoring and her commitment to launching the careers of the next generation of scientists. Her mentoring awards include both local and international recognition.[5] She established a training program for graduate students to support training in the study of viral diseases and how viruses evolve even before the COVID pandemic highlighted the need to such training. Her trainees have taken a variety of position in academia, government, industry and a broader range of areas. In academia. Her former trainees have taken faculty positions at Baylor, Columbia, Emory, Harvard, Stanford U Michigan, U Washington, and other Universities focused on research and/or teaching. Former trainees have also attained positions in global health, at the Gates Foundation, the African Academy of Sciences, and in government at the CDC and NIH and the Kenya Medical Research Institute, Other trainees have secured roles in science policy and diversity and inclusion offices and some have written novels with a science focus.

Contributions to the Practice of Science

[edit]

Overbaugh has actively contributed to improving the practice of science. She has written about effective mentoring from the perspective of a highly productive scientist who has also garnered multiple mentoring awards.[58] She is also well recognized for having a lab that supports work-life balance and as a result, the journal Nature solicited a commentary on this topic.[59] There she highlighted “there must be room for those who want that balance, otherwise creative people with the potential to make significant contributions to scientific discovery will be excluded”. She has written about differences in publication rates in high-profile journals based on gender and argued for better tracking to improve this imbalance.[60][61] She also lectures on the practice peer-review in ethics forums having served as Chair of NIH grant review panels and as Journal editor.

Advocacy for diversity in science

[edit]

Overbaugh has been a strong advocate for diversity in science during her career. Overbaugh was the founding faculty lead for Hutch United,[62] a grass roots effort established in 2013 and led by trainees to help promote the success of underrepresented groups in science and those who otherwise felt on the fringes. She has also served in an advisory role in the Fred Hutch Office of Diversity, Equity and Inclusion, and was selected as one of three Fred Hutch faculty to present at the 2021 DEI Summit.[63] In her role as senior vice president and director of the Office of Education and Training at the Fred Hutch, she helped oversee efforts to create a more diverse scientific workforce, she served as advocate for diversity in science at all levels and helped provide support for new faculty launching their careers. Overbaugh has published papers in scientific journals pointing out gender bias in the review process.[64][65]

Overbaugh has the distinction of having hosted the most diverse lab at Fred Hutch. Among the 64 graduate students and postdoctoral fellows she has trained, 20 are members of the BIPOC community and 10 are members of the LGBTQ+ community. She has published 160 peer-reviewed publications with African co-authors, and has mentored numerous African scientists for periods ranging from short-term technical training to masters and PhD level training. Her citation for the Nature Mentorship Award calls out her strengths mentoring African scientists: "She has the patience to listen to and deal with culture shocks and adjustment to new surroundings and a different system of training and education."[66]

Overbaugh's place as a role model and mentor for underrepresented groups in science has been recognized in multiple other ways including by the University of Washington School of Medicine in 2007.[67] Her leadership was also highlighted in the introductory remarks ahead of her honorary opening lecture at the premiere meeting in the HIV field.[68] There it was noted that she has a reputation as a ‘proponent for women’s rights’. In that lecture, Overbaugh highlighted her collaborative and bilateral research with Kenyan partners and emphasized her view of the importance of supporting training of aspiring African scientists.

Leadership and institutional recognition

[edit]

Overbaugh has served in numerous leadership roles in the field nationally and internationally, including chair of NIH grant review panels on both HIV molecular biology and HIV immunology, as Chair of the Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Diseases Award committee, and as chair of Conference on Retroviruses and Opportunistic Infections (CROI) as well as other major meetings.

Overbaugh also had major leadership role within her institutions. In 2017, Overbaugh was appointed the inaugural Hutch associate director for graduate education.[69] In that capacity, she was subsequently named the inaugural senior vice president for education and in these leadership roles she established a new Office of Education and Training at the Fred Hutch.[70] Overbaugh also established and led an NIH funded program to support and train graduate students pursuing research on viral evolution and pathogenesis across Seattle institutions and she served in a leadership role in the Medical Sciences Training program.

Her education and career development efforts along with her scientific excellence were widely recognized in the Seattle community. Despite never being given the tenure-track position afforded her male colleagues while at University of Washington, various university selection committees recognized her scientific excellence, both while there and when she moved to the Fred Hutch. In 1994, as a junior faculty member at UW, Overbaugh was selected to present the New Investigator lecture to the University of Medical School.[71] In 2011, while at Fred Hutch, she was honored as the distinguished scientist of the year by the University of Washington School of Medicine.[71] As part of this recognition, she presented her work to the School of Medicine in the Science in Medicine seminar series in a talk entitled “Deciphering the biology of HIV transmission: A basic scientist’s journey into interdisciplinary, international HIV research”. The University of Washington also recognized Overbaugh with an outstanding mentoring award in 2007.[72] The Fred Hutch soon followed, bestowing their faculty mentoring award on Overbaugh in 2008.[73]

Resignation from leadership: In early 2022, Overbaugh was placed on administrative leave from the Fred Hutchinson Cancer Research Center in order to conduct an independent external investigation.[74][75] The investigation was prompted by an anonymous complaint regarding a Cancer Research Center Halloween Party in 2009 where she was asked to dress as Michael Jackson as part of a group "Thriller" costume and darkened her face for this role.[74] This was determined to be an isolated incident, and an interview of her peers and coworkers failed to reveal any pattern of inappropriate behavior of any kind in the past or at any time while employed at Fred Hutch in her twenty-three year tenure. Overbaugh offered a public apology to the entire Fred Hutch community for any offense as described by the president of the Hutch in the town hall: "As part of [an] education healing process, Julie wanted to offer her direct apology to our community. I commend this." The external independent investigation report noted her decades-long leadership at Fred Hutch in support of equity and inclusion report and concluded that "Dr. Overbaugh’s individual contributions to DEI efforts at Fred Hutch have been significant, wide-reaching, and long-standing."[74]

Having established the Office of Education and the position of senior vice president for education and serving in leadership roles in education for a decade at the Hutch, Overbaugh decided to step down from her administrative leadership roles to focus on her research on COVID, HIV and other emerging global pathogens. As the Hutch President reported: “Julie has offered to step down from her role as Senior Vice President of Education and Training and I have accepted her resignation”. “She will continue to be a prominent investigator at the Fred Hutch in the Human Biology Division working on viruses that affect so many people around the world”.[76]

Research focus

[edit]

Overbaugh's laboratory continues to study viral and immune factors that contribute to infection and disease in global populations at high risk of HIV infection.[77] This includes continued studies of mother-infant HIV transmission and infant responses to infection. An aspect of the work of the lab includes defining how antibodies evolve to become more potent.[78][79][80]

During the COVID pandemic, her laboratory started to apply their expertise in viral immunology to advance research on SARS-CoV-2 immunity.  They developed tools that allows comprehensive profiling of antibody responses and pathways of escape.[81] They  are using these profiles to isolate and study antibodies to SARS-CoV-2, with a focus on identifying broad and potent antibodies that can recognize emerging variants of concern. She has also contributed to the discussions of re-infection.[82]

The lab is studying other globally important pathogens such as Zika virus.[83] They also study innate immune factors and their role in inhibiting virus replication.[30][84][85]

References

[edit]
  1. ^ a b Marshall, Lisa (June 1, 2012). "AIDS Interrupted". University of Colorado. Retrieved August 26, 2021.
  2. ^ a b c d Myers, Shelley (January 31, 1999). "Delone grad gets $700,000 grant to research HIV virus". The Evening Sun. Retrieved August 26, 2021 – via newspapers.com.
  3. ^ "Overbaugh Aids Lady Husky Bid". The Evening Sun. January 17, 1978. Retrieved August 26, 2021 – via newspapers.com.
  4. ^ Fuller, Jim (November 25, 2000). "Doctor's orders: Follow UConn". The Middletown Press. Retrieved August 26, 2021.
  5. ^ a b c d Richards, Sabrina (December 2, 2016). "HIV researcher Dr. Julie Overbaugh wins Nature mentorship award". Fred Hutch. Retrieved August 26, 2021.
  6. ^ a b Garnick, Coral (December 16, 2016). "'Unusual scientist' Julie Overbaugh studies HIV transmission". Puget Sound Business Journal. Retrieved August 26, 2021.
  7. ^ Richards, Sabrina (February 10, 2017). "Spotlight on Julie Overbaugh". Fred Hutch. Retrieved August 26, 2021.
  8. ^ Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, Ndinya-Achola J, Bwayo J, Onyango FE, Hughes J, Kreiss JK. Effect of breastfeeding and formula feeding on transmission of HIV-1: A randomized clinical trial. JAMA. 283(9): 1167-1174, 2000.
  9. ^ Rousseau CM, Nduati RW, Richardson BA, John-Stewart GC, Mbori-Ngacha DA, Kreiss JK, Overbaugh J. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis. 190(10): 1880-1888, 2004.
  10. ^ Rousseau CM, Nduati RW, Richardson BA, Steele MS, John-Stewart GC, Mbori-Ngacha DA, Kreiss JK, Overbaugh J. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis. 187(5): 741-747, 2003.
  11. ^ Milligan C, Richardson BA, John-Stewart G, Nduati R, Overbaugh J. Passively acquired antibody–dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality. Cell Host Microbe.17(4): 500-506, 2015.
  12. ^ Yaffe Z, Naimen NE, Slyker J, Wines BD, Richardson BA, Bosire R, Farquhar C, Ngacha M, Nduati R, John-Stewart G, Overbaugh J. Improved HIV-infected infant survival is correlated with high levels of HIV-specific ADCC activity in multiple cohorts. Cell Rep Med. 20;2(4), 2021.
  13. ^ Goo L, Chohan V, Nduati R, Overbaugh J. Early development of broad neutralizing antibodies in HIV-1 infected infants. Nat Med. 20(6): 655-658, 2014.
  14. ^ Simonich CA, Williams KL, Verkerke HP, Williams JA, Nduati R, Lee KK and Overbaugh J. HIV-1 neutralizing antibodies with limited hypermuation from an infant. Cell. 166(1): 77-87, 2016.
  15. ^ Simonich C, Doepker L, Duncan R, Williams JA, Dhar A, Yaffe Z, Gentles L, Small CT, Oliver B, Vigdorovich V, Prasad VM, Nduati R, Sather DN, Lee KK, Matsen FA, Overbaugh J. Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage. Nat Commu. 10(1): 2190, 2019
  16. ^ Richards, Sabrina (November 27, 2017). "Insights from infants could inform HIV vaccine design". Fred Hutch. Retrieved August 26, 2021.
  17. ^ 1. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, Rainwater SM, Overbaugh J. Neutralization escape variants of human immunodeficiency virus type 1are transmitted from mother to infant. J Virol. 80(2): 835-844, 2006.
  18. ^ Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med. 5(5): 535-541, 1999.
  19. ^ Overbaugh J, Rudensey LR. Alterations in potential sites for glycosylation during evolution of the simian immunodeficiency virus envelope gene in macaques. J Virol. 66(10): 5937-5948, 1992.
  20. ^ 1. Chackerian B, Rudensey LM, Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol. 71(10): 7719-7727, 1997.
  21. ^ Overbaugh J, Donahue PR, Quackenbush SL, Hoover EA, Mullins JI. Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency in cats. Science. 239(4842): 906-910, 1988.
  22. ^ Overbaugh J, Riedel N, Hoover EA, Mullins JI. Transduction of endogenous envelope genes by feline leukemia virus in vitro. Nature. 332(6166): 731-734, 1988.
  23. ^ Anderson MM, Lauring AL, Burns CC, Overbaugh J. Identification of a cellular cofactor required for infection by feline leukemia virus. Science. 287(5459): 1828-1830, 2000
  24. ^ Lauring AS, Anderson MM, Overbaugh J. Specificity in receptor usage by T-cell-tropic feline leukemia viruses: Implications for the in vivo tropism of immunodeficiency-inducing variants. J Virol. 75(19): 8888-8898, 2001.
  25. ^ Cheng HH, Anderson MM, Hankenson FC, Johnston L, Kotwaliwale CV, Overbaugh J. Envelope determinants for dual-receptor specificity in feline leukemia virus subgroup A and T variants. J Virol. 80(4): 1619-1628, 2006.
  26. ^ Rohn JL, Moser MS, Gwynn SR, Baldwin DN, Overbaugh J. In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant. J Virol. 72(4): 2686-2696, 1998.
  27. ^ Mendoza R, Anderson MM, Overbaugh J. A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A. J Virol. 80(7): 3378-3385, 2006.
  28. ^ Humes D, Overbaugh J. Adaptation of Subtype A Human Immunodeficiency Virus Type 1 Envelope to Pig-Tailed Macaque Cells. J Virol. 85(9): 4409-20, 2011.
  29. ^ Humes D, Emery S, Laws E, Overbaugh J. A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection. J Virol. 86(23): 12472-12483, 2012
  30. ^ a b Boyd DF, Sharma A, Humes D, Cheng-Mayer C and Overbaugh J. Adapting SHIVs in vivo selects for Envelope-mediated Interferon- α resistance. PLos Pathog. 12(7): e1005727, 2016.
  31. ^ Cairns J, Overbaugh J, Miller S. The origin of mutants. Nature. 335(6186): 142-145, 1988.
  32. ^ Poss M, Martin HL, Kreiss JK, Granville L, Chohan B, Nyange P, Mandaliya K, Overbaugh J. Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol. 69(12): 8118-8122, 1995.
  33. ^ Long EM, Martin HL Jr, Kreiss JK, Rainwater SM, Lavreys L, Jackson DJ, Rakwar J, Mandaliya K, Overbaugh J. Gender differences in HIV-1 diversity at time of infection. Nat Med. 6(1): 71-75, 2000.
  34. ^ Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, Rainwater SM, Overbaugh J. Neutralization escape variants of human immunodeficiency virus type 1are transmitted from mother to infant. J Virol. 80(2): 835-844, 2006.
  35. ^ Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, Ndinya-Achola JO, Kreiss JK, Overbaugh J. Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS. 18(4): 615-619, 2004.
  36. ^ Chohan B, Lavreys L, Rainwater SM, Overbaugh J. Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol. 79(16): 10701-10708, 2005.
  37. ^ Piantadosi A, Chohan B, Chohan V, McClelland RS, Overbaugh J. Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog. 3(11): e177, 2007.
  38. ^ 1. Ronen K, McCoy CO, Matsen FA, Boyd DF, Emery S, Odem-Davis K, Jaoko W, Mandaliya K, McClelland RS, Richardson BA, Overbaugh J. HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog. 9(8): e1003593, 2013.
  39. ^ Blish CA, Dogan OC, Derby NR, Nguyen MA, Chohan B, Richardson BA, Overbaugh J. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol. 82(24): 12094-12103, 2008.
  40. ^ Ronen K, Richardson BA, Graham SM, Jaoko W, Mandaliya K, McClelland RS, Richardson BA, Overbaugh J. HIV-1 superinfection is associated with an accelerated viral load increase but has a limited impact on disease progression. AIDS. 28(15): 2281-2286, 2014.
  41. ^ Ronen K, Dingens AS, Graham SM, Jaoko W, Mandaliya K, McClelland RS, Overbaugh J. Comprehensive Characterization of Humoral Correlates of Human Immunodeficiency Virus 1 Superinfection Acquisition in High-Risk Kenyan Women. EBioMedicine. 18: 216-244, 2017.
  42. ^ Dingens AS, Haddox HK, Overbaugh J, Bloom JD. Comprehensive Mapping of HIV-1 Escape from Broadly Neutralizing Antibody. Cell Host Microbe. 21(6): 777-787, 2017.
  43. ^ Dingens AS, Arenz D, Weight H, Overbaugh J, Bloom JD. An antigenic atlas of HIV-1 escape from broadly neutralizing antibodies. Immunity. 50(2): 520-532.e3, 2019.
  44. ^ Diab, A. (May 18, 2020). "Cracking the code of HIV-1 entry into macaque cells". Fred Hutch. Retrieved August 26, 2021.
  45. ^ Garrett ME, Itell HL, Crawford K, Basom R, Bloom JD, Overbaugh J. Phage-DMS: a comprehensive method for fine mapping of antibody epitopes. iScience. 23(10): 101622, 2020.
  46. ^ Garrett ME, Galloway J, Chu HY, …, Weight, H, Matsen FA, Overbaugh J. High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. Cell. 184:2927-2938, 2021.
  47. ^ Panteleeff DD, John G, Nduati R, Mbori-Ngacha D, Richardson B, Kreiss J, Overbaugh J. Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. J Clin Microbiol. 37(2): 350-353, 1999.
  48. ^ Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, Panteleeff DD, Jagodzinski LL, Michael NL, Nduati R, Bwayo J, Kreiss JK, Overbaugh J. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol. 38(7): 2688-2695, 2000.
  49. ^ DeVange-Panteleeff D, Emery S, Richardson BA, Rousseau C, Benki S, Bodrug S, Kreiss JK, Overbaugh J. Validation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay for genital swabs and breastmilk samples. J Clin Microbiol. 40(11): 3929-2937, 2002.
  50. ^ Itell HL, Weight H, Fish CS, Logue JK, Franko N, Wolf CR, McCulloch DJ, Galloway J, Matsen FA, Chu HY, Overbaug J. SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma. Microbiol Spectr. 9(2):e0129821, 2021
  51. ^ Carroll, John (November 29, 2011). "Julie Overbaugh - FierceBiotech's 2011 Women in Biotech". Fierce Biotech. Retrieved August 26, 2021.
  52. ^ "Overbaugh elected to the American Academy of Microbiology". Fred Hutch. May 9, 2011. Retrieved August 26, 2021.
  53. ^ "Overbaugh wins scientific leadership award". Fred Hutch. August 8, 2011. Retrieved August 26, 2021.
  54. ^ "HIV researcher Dr. Julie Overbaugh gives Bernard Fields Lecture at CROI". Fred Hutch. March 5, 2018. Retrieved October 4, 2021.
  55. ^ "Julie Overbaugh". American Academy of Arts and Sciences. Retrieved August 26, 2021.
  56. ^ Richards, Sabrina (April 23, 2020). "Dr. Julie Overbaugh elected to American Academy of Arts & Sciences". Retrieved August 26, 2021.
  57. ^ "Dr. Julie Overbaugh elected to National Academy of Sciences". Fred Hutch. April 27, 2021. Retrieved October 4, 2021.
  58. ^ Clynes, Corbett, Overbaugh |Why we need good mentoring. Nature Cancer Reviews, 2019
  59. ^ Overbaugh J. 24/7 isn’t the only way: A healthy work-life balance can enhance research. Nature. 477(7362): 27-28, 2011.
  60. ^ Overbaugh J. Gender Bias: track revisions and appeals. Nature: 543: 40, 2017.
  61. ^ Overbaugh J. Defining the barriers to women publishing in high-impact journals. J Virol. 92(7), 2018.
  62. ^ "Hutch United".
  63. ^ "2021 Fred Hutch DEI Summit | Your role in supporting and engaging the next generation at Fred Hutch". YouTube. 11 June 2021.
  64. ^ Overbaugh, Julie (2017). "Gender bias: Track revisions and appeals". Nature. 543 (7643): 40. Bibcode:2017Natur.543...40O. doi:10.1038/543040a. PMID 28252055.
  65. ^ Overbaugh, Julie (2018). "Defining the Barriers to Women Publishing in High-Impact Journals". Journal of Virology. 92 (7). doi:10.1128/JVI.02127-17. PMC 5972867. PMID 29367249.
  66. ^ Campbell, Philip (2016). "Mentoring awards: Leading by example". Nature. 540 (7632): 305–306. doi:10.1038/nj7632-305a. S2CID 185271466.
  67. ^ url=https://faculty.uwmedicine.org/wp-content/uploads/2021/10/EMAIL-BODY_Mentoring-Award-2021.pdf
  68. ^ "HIV researcher Julie Overbaugh gives Bernard Fields Lecture at CROI". Fred Hutch. March 5, 2018. Retrieved October 4, 2021.
  69. ^ Richards, Sabrina (March 23, 2017). "Good News: HIV researcher Julie Overbaugh leads Hutch graduate education ... and more". Fred Hutch. Retrieved August 26, 2021.
  70. ^ < url: https://centernet.fredhutch.org/cn/n/2021/09/overbaugh-promoted-svp-education.html>
  71. ^ a b <url:https://www.uwmedicine.org/sites/stevie/files/2019-07/2019-SIM%20Historic%20Database_1993-2019.pdf>
  72. ^ <url: https://faculty.uwmedicine.org/wp-content/uploads/2021/10/EMAIL-BODY_Mentoring-Award-2021.pdf>
  73. ^ "Student/Postdoc Advisory Committee".
  74. ^ a b c Fleming Reed, Marcella. "Fred Hutch Overbaugh Investigation Report". Retrieved April 18, 2022.
  75. ^ "Fred Hutch statement on racist act involving a senior staff member". Fred Hutch. 16 February 2022. Retrieved February 16, 2022.
  76. ^ "Fred Hutch town hall". YouTube. 16 February 2022.
  77. ^ "Overbaugh Lab". Fred Hutch. Retrieved October 4, 2021.
  78. ^ Shipley MM, Prasad VM, Doepker LE, Dingens A, Ralph D, Harkins E, Dhar A, Arenz D, Chohan V, Weight H, Mandaliya K, Bloom JD, Matsen FA, Lee KK, Overbaugh J. Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection. eLife. 10:e68110, 2021.
  79. ^ Doepker LE, Danon S, Harkins E, Ralph D, Yaffe Z, Dhar Amrit, Wagner C, Stumpf M, Arenz A, Williams JA, Lee KK, Matsen FA, Overbaugh J. Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies. Elife. 10: e63444, 2021.
  80. ^ Simonich C, Doepker L, Duncan R, Williams JA, Dhar A, Yaffe Z, Gentles L, Small CT, Oliver B, Vigdorovich V, Prasad VM, Nduati R, Sather DN, Lee KK, Matsen FA, Overbaugh J. Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage. Nat Commu. 10(1): 2190, 2019.
  81. ^ Garrett, M. E.; Galloway, J.; Chu, H. Y.; Itell, H. L.; Stoddard, C. I.; Wolf, C. R.; Logue, J. K.; McDonald, D.; Matsen Fa, 4th; Overbaugh, J. (November 16, 2020). "High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies". Cell. 184 (11): 2927–2938. bioRxiv 10.1101/2020.11.16.385278. doi:10.1016/j.cell.2021.04.045. PMC 7685320. PMID 33236010.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  82. ^ Overbaugh J. Understanding protection from SARS-CoV-2 reinfection. Nature Med. 26(11): 1680-1681, 2020.
  83. ^ Gobillot, T. A.; Kikawa, C.; Lehman, D. A.; Kinuthia, J.; Drake, A. L.; Jaoko, W.; Mandaliya, K.; John-Stewart, G.; McClelland, R. S.; Overbaugh, J. (August 4, 2020). "Zika virus circulates at low levels in Western and Coastal Kenya". The Journal of Infectious Diseases. 222 (5): 847–852. doi:10.1093/infdis/jiaa158. PMC 7399697. PMID 32242626.
  84. ^ Sharma A, McLaughlin RN, Basom RS, OhAinle M, Kikawa C, Yount JS, Emerman M, Overbugh J. Macaque interferon-induced transmembrane proteins limit replication of SHIV strains in an Envelope-dependent manner. PLoS Pathog. 15(7): e1007925, 2019.
  85. ^ Gobillot T, Humes D, Sharma A, Kikawa C, Overbaugh J. The robust restriction of Zika virus by type-I Interferon in A549 cells varies by viral lineage and is not determined by IFITM3. Viruses. 12(5): 503, 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Julie_Overbaugh&oldid=1234427714"